Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Initial Efficacy of BAT8008 for Injection in Patients With Advanced Solid Tumor

Next Previous
Search
Trial Profile

A Multicenter, Open Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Initial Efficacy of BAT8008 for Injection in Patients With Advanced Solid Tumor

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BAT 8008 (Primary)
  • Indications Carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bio-Thera Solutions

    • Most Recent Events

    • 14 Apr 2025 According to Bio-Thera Solutions media release, data from this study will be presented at at the 2025 ASCO Annual Meeting
    • 08 Mar 2023 According to a Bio-Thera solutions media release, company announced today that dosing has begun in this trial.
    • 08 Mar 2023 Status changed to recruiting , according to a Bio-Thera solutions media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top